《Lancet Infectious Diseases》雜志的最新年發文量為135篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章,以保持其在傳染病學領域的學術影響力。
該刊聚焦于醫學-傳染病學領域的前沿研究,致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 較慢,6-12周 。
Lancet Infectious Diseases 雜志發文統計
文章名稱引用次數
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis465
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis327
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016128
- Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016124
- Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission103
- A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study90
- Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study87
- Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial87
- The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 201786
- Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase open-label, single-arm, dose-escalation trial76
國家/地區發文量
- USA457
- England363
- France145
- Switzerland141
- CHINA MAINLAND124
- Australia119
- GERMANY (FED REP GER)110
- Netherlands95
- South Africa90
- Italy84